A promising new therapeutic target in the RAAS appears to be the PRR (prorenin receptor), which is associated with VSMC proliferation, neovascularization, endothelial dysfunction, and cardiovascular disease progression.86,385. The gene discussed is ATP6AP2; the disease is cardiovascular disorder.